Acalabrutinib, as monotherapy or in combination with obinutuzumab, continued to improve progression-free survival vs obinutuzumab and chemotherapy in patients with treatment-naive chronic lymphocytic leukemia, regardless of genomic marker status.
A closer look at some of the approaches being used across The US Oncology Network to improve patient access can provide helpful insight into how practices can meet the growing need for their services.
Ontada®, a McKesson business dedicated to leveraging oncology real-world data and evidence, clinical education, and provider technology, was awarded a competitive contract with the U.S. Food and Drug Administration to advance the use of real-world data in the U.S. community oncology setting.